Therapy Type: Small Molecule
Target Type: Other Neurotransmitter Systems
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Cortex Pharmaceuticals, Inc.
Approved for: None
CX516 is a so-called ampakine, a molecule that potentiates currents mediated by AMPA-type glutamate receptors. As a class, these drugs enhance AMPA-receptor activity by slowing deactivation and attenuating desensitization of AMPA receptor currents, thus increasing synaptic responses and enhancing long-term potentiation (reviewed in Arai and Kessler, 2007).
- Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets. 2007 May;8(5):583-602. PubMed.
No Available Further Reading